✦ LIBER ✦

485 Influence of disease free interval on the efficacy of capecitabine-bevacizumab for HER2-negative metastatic breast cancer (MBC) in the RIBBON-1 trial

✍ Scribed by A. Brufsky; O. Ponomarova; S. Tjulandin

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

475 Consistent progression-free survival

✍ J. O'Shaughnessy; V. Dieras; S. Chan 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 44 KB

5016 Efficacy in patient subgroups in RI

✍ V. Dieras; J. Glaspy; A. Brufsky; I. Bondarenko; O. Lipatov; E.A. Perez; S. Chan 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 49 KB

Bevacizumab plus paclitaxel versus bevac

✍ Lang, Istvan; Brodowicz, Thomas; Ryvo, Larisa; Kahan, Zsuzsanna; Greil, Richard; 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 420 KB

476 PFS by patient subgroup for standard

✍ I. Bondarenko; J. Glaspy; A. Brufsky; O. Lipatov; E.A. Perez; S. Chan; X. Zou; S 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 45 KB

Comment on Wang et al.: The efficacy of

✍ Li, Jun; Yao, Yunfeng; Jing, Juehua 📂 Article 📅 2014 🏛 S. Karger AG 🌐 English ⚖ 74 KB

RIBBON-2: A Randomized, Double-Blind, Pl

✍ Datko, F.M.; Dickler, M.N. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 295 KB